The FDA approved two biomarkers of renal cell cycle arrest, tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7), for assessing the possibility of severe AKI development. The gene discussed is TIMP2; the disease is acute kidney injury.